Objective:

To provide a novel treatment for severe-to-profound sensorineural hearing loss associated with biallelic variants in the OTOF gene.

Key Findings:

• 16 of 20 patients met the primary endpoint of improvement in pure tone audiometry thresholds to 70 decibel hearing level or better at 24 weeks.
• 14 of 20 patients showed auditory brainstem responses at 90 decibel hearing level or better at 24 weeks.
• 5 of 12 patients maintained hearing thresholds within the normal range by week 48.

Interpretation:

The therapy offers a potential breakthrough for patients with OTOF-related hearing loss, which currently lacks effective treatment options.

Limitations:

• The therapy is not recommended for patients with inaccessible inner ear or those with prior cochlear implants.
• Continued approval is dependent on further confirmation of clinical benefits.

Conclusion:

Lunsotogene parvec-cwha represents a significant advancement in treating a rare form of hearing loss, pending further validation of its long-term efficacy.